AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

# AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion. **Read the full article:** [CNBC](https://www.cnbc.com/2026/09/08/astrazeneca-copd-drug-tozorakimab-shows-positive-late-stage-trial-results.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*